Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7750774 | 0.86 | MEN1 (0.67) | MEN1KMT2ASIGMAR1RECQLMTNR1A | |
| SCHEMBL25083434 | 0.85 | KMT2A (0.52) | MEN1KMT2ASIGMAR1RECQLCASP2 | |
| SCHEMBL18513030 | 0.85 | MEN1 (0.71) | MEN1KMT2ASIGMAR1RECQLCASP2 | |
| SCHEMBL9794 | 0.84 | MEN1 (0.56) | MEN1KMT2ASIGMAR1RECQLMTNR1A | |
| SCHEMBL26469321 | 0.83 | MEN1 (0.68) | MEN1KMT2ARECQLCASP2 | |
| SCHEMBL20000768 | 0.82 | CASP2 (0.55) | KMT2ASIGMAR1CASP2 | |
| SCHEMBL24489203 | 0.81 | MEN1 (0.44) | MEN1KMT2ASIGMAR1RECQLMTNR1A | |
| SCHEMBL20198781 | 0.81 | SIGMAR1 (0.50) | MEN1KMT2ASIGMAR1MLYCD | |
| SCHEMBL17471845 | 0.81 | SIGMAR1 (0.50) | MEN1KMT2ASIGMAR1MLYCDRECQL | |
| SCHEMBL21016292 | 0.81 | SIGMAR1 (0.50) | MEN1KMT2ASIGMAR1MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-06-27 | — | — | US | disclosed |
| US-20230132202-A1 | Polymeric Binder and High Molecular Weight Polymer Antifouling Compositions | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-04-27 | — | — | US | disclosed |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2023-02-09 | — | — | US | disclosed |
| US-11208388-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-14 | — | — | US | disclosed |
| US-20180148472-A1 | AFFINITY-ASSISTED PROTEIN MODIFICATION AND RECYCLING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-31 | — | — | US | disclosed |
| US-20180147326-A1 | Antifouling Polymeric Coating Compositions | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-31 | — | — | US | disclosed |
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120316173-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | US | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | MEN1 440/4885KMT2A 797/4885SIGMAR1 3758/4885 |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | MEN1 440/4885KMT2A 797/4885SIGMAR1 3758/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | MEN1 1427/4885KMT2A 1042/4885SIGMAR1 4398/4885 |
| US-11685714-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BUB1B, KIF5B, TK1 | MEN1 1660/4885KMT2A 2705/4885SIGMAR1 4572/4885 |
| US-11208388-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | MEN1 440/4885KMT2A 797/4885SIGMAR1 3758/4885 |
| US-20120316173-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | CNR2, CNR1, OPRL1 | MEN1 4811/4885KMT2A 3720/4885SIGMAR1 210/4885 |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | MEN1 4400/4885KMT2A 1441/4885SIGMAR1 3065/4885 |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | MEN1 3205/4885KMT2A 1854/4885SIGMAR1 1291/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | MEN1 1223/4885KMT2A 2532/4885SIGMAR1 479/4885 |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | RCC2, REN, VHL | MEN1 6/4885KMT2A 3583/4885SIGMAR1 4538/4885 |
| US-20190077752-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BUB1B, KIF5B, TK1 | MEN1 1660/4885KMT2A 2705/4885SIGMAR1 4572/4885 |
| US-20180148472-A1 | AFFINITY-ASSISTED PROTEIN MODIFICATION AND RECYCLING | MRPL21, ACP1, MAX | MEN1 3158/4885KMT2A 1934/4885SIGMAR1 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.